Qiagen still on the acquisition trail, but looking for quality, not quantity
This article was originally published in Clinica
Qiagen is bucking the global trend for belt-tightening, having dipped into its wallet to make strategic investments and acquire two companies outright. Madeleine Armstrong spoke to Jean-Pascal Viola, vice-president of corporate business development Americas, about Qiagen's acquisition strategy and what kind of companies it is looking for in future
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.